Trial Profile
Phase II Trial Of Neoadjuvant Concurrent Capecitabine, RHUMAB VEGF (Avastin) And Radiotherapy In Patients Presenting With Locally Advanced Rectal Cancer
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 24 Nov 2014
Price :
$35
*
At a glance
- Drugs Bevacizumab (Primary) ; Capecitabine (Primary)
- Indications Colorectal cancer
- Focus Therapeutic Use
- 17 Nov 2009 Actual end date (Jan 2009) and actual number of patients (25) added as reported by ClinicalTrials.gov.
- 12 Feb 2009 Status changed from active, no longer recruiting to completed, as reported by ClinicalTrials.gov.
- 06 Nov 2008 Planned end date changed from 1 Feb 2008 to 1 Dec 2008, as reported by ClinicalTrials.gov.